Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2009/091/000722
CTRI/2009/091/000722
Completed
Phase 2

A Prospective Observational Study To Evaluate Long-Term Safety And Functional Status Of Subjects With Rheumatoid Arthritis Previously Enrolled In Studies Of CP-690,550 - Not applicable

Pfizer Limited0 sites300 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Pfizer Limited
Enrollment
300
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Ages Eligible for Study:18 Years and older,
  • •Genders Eligible for Study:Both,
  • •Accepts Healthy Volunteers:No,
  • •Sampling Method:Non\-Probability Sample,
  • •Study Population
  • •Subjects who have received at least one dose of study drug and ceased participation in any Phase 2B or 3 randomized, controlled or open\-label (qualifying) study of CP\-690,550 for the treatment of RA, but are no longer receiving CP\-690,550\.
  • •Inclusion Criteria:
  • •\- Subjects who have completed all participation in any other Phase 2B or Phase 3 studies of CP\-690,550 for rheumatoid arthritis.

Exclusion Criteria

  • •Any subject who refuses consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2006-006373-25-ATPfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK300
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2006-006373-25-SEPfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK300
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2006-006373-25-CZPfizer Inc. 235 East 42nd Street, New York, NY10017300
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2006-006373-25-BGPfizer Inc. 235 East 42nd Street, New York, NY10017300
Active, not recruiting
Not Applicable
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/A
EUCTR2006-006373-25-FIPfizer Inc. 235 East 42nd Street, New York, NY10017300